Large language model evaluation in autoimmune disease clinical questions comparing ChatGPT 4o, Claude 3.5 Sonnet and
Juntao Ma1, Jie Yu1, Anran Xie1
1Department of Laboratory Medicine, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Abstract:
Large language models (LLMs) have established a presence in providing medical services to patients and supporting clinical practice for doctors. To explore the ability of LLMs in answering clinical questions related to autoimmune diseases, this study was designed with 65 questions related to autoimmune diseases, covering five domains: concepts, report interpretation, diagnosis, prevention and treatment, and prognosis. Types of diseases include Sjögren's syndrome, systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, and others. These questions were answered by three LLMs: ChatGPT 4o, Claude 3.5 Sonnet, and Gemini 1.5 Pro. The responses were then evaluated by 8 clinicians based on criteria including relevance, completeness, accuracy, safety, readability, and simplicity. We analyzed the scores of the three LLMs across five domains and six dimensions and compared their accuracy in answering the report interpretation section with that of two senior doctors and two junior doctors. The results showed that the performance of the three LLMs in the evaluation of autoimmune diseases significantly surpassed that of both junior and senior doctors. Notably, Claude 3.5 Sonnet excelled in providing comprehensive and accurate responses to clinical questions on autoimmune diseases, demonstrating the great potential of LLMs in assisting doctors with the diagnosis, treatment, and management of autoimmune diseases.
More Related Videos
06:50A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases
Published on: May 29, 2020
03:14Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness
Published on: December 6, 2024
